FDA Approved VUNO’s AI Chest X-ray Diagnostic Device

Medical AI company VUNO announced on the 19th that its AI-based chest X-ray diagnostic device, VUNO Med-Chest X-ray Triage, has received approval from the U.S. Food and Drug Administration (FDA).

VUNO Med-Chest X-ray Triage is an AI solution that analyzes chest X-ray images to quickly detect and categorize diseases. It can automatically assess conditions such as pneumothorax and pleural effusion, providing rapid diagnostic results to healthcare providers. VUNO explains that the solution can significantly enhance response times in emergency settings.

A VUNO representative commented, “This FDA approval is expected to accelerate our entry into the U.S. market.”

This is VUNO’s second FDA-approved product, following the approval of its AI-based brain quantification device, VUNO Med-DeepBrain, in October last year. Since then, VUNO has been actively promoting its solutions to local medical institutions through its U.S. subsidiary to strengthen its presence in the American market.

VUNO is also seeking FDA approval for VUNO Med-DeepCARS, an AI-based device for monitoring cardiac arrest risk. The company aims to expand its product portfolio in the U.S. market, driving forward its global expansion plans.